Display options
Cite
Roberts LN, Lisman T, Stanworth S, et al. Periprocedural management of abnormal coagulation parameters and thrombocytopenia in patients with cirrhosis: Guidance from the SSC of the ISTH. J Thromb Haemost. 2021;20(1):39-47doi: 10.1111/jth.15562.
Roberts, L. N., Lisman, T., Stanworth, S., Hernandez-Gea, V., Magnusson, M., Tripodi, A., & Thachil, J. (2022). Periprocedural management of abnormal coagulation parameters and thrombocytopenia in patients with cirrhosis: Guidance from the SSC of the ISTH. Journal of thrombosis and haemostasis : JTH, 20(1), 39-47. https://doi.org/10.1111/jth.15562
Roberts, Lara N, et al. "Periprocedural management of abnormal coagulation parameters and thrombocytopenia in patients with cirrhosis: Guidance from the SSC of the ISTH." Journal of thrombosis and haemostasis : JTH vol. 20,1 (2022): 39-47. doi: https://doi.org/10.1111/jth.15562
Roberts LN, Lisman T, Stanworth S, Hernandez-Gea V, Magnusson M, Tripodi A, Thachil J. Periprocedural management of abnormal coagulation parameters and thrombocytopenia in patients with cirrhosis: Guidance from the SSC of the ISTH. J Thromb Haemost. 2022 Jan;20(1):39-47. doi: 10.1111/jth.15562. Epub 2021 Nov 08. PMID: 34661370.
Copy Download .nbib Format: NLM
Share it on

J Thromb Haemost. 2022 Jan;20(1):39-47. doi: 10.1111/jth.15562. Epub 2021 Nov 08.

Periprocedural management of abnormal coagulation parameters and thrombocytopenia in patients with cirrhosis: Guidance from the SSC of the ISTH.

Journal of thrombosis and haemostasis : JTH

Lara N Roberts, Ton Lisman, Simon Stanworth, Virginia Hernandez-Gea, Maria Magnusson, Armando Tripodi, Jecko Thachil

Affiliations

  1. King's Thrombosis Centre, Department of Haematological Medicine, King's College Hospital, London, UK.
  2. Surgical Research Laboratory and Section of Hepatobiliary Surgery and Liver Transplantation, Department of Surgery, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
  3. Transfusion Medicine, NHS Blood and Transplant, Oxford, UK.
  4. Department of Haematology, Oxford University Hospitals, NHS Foundation Trust, Oxford, UK.
  5. Radcliffe Department of Medicine, University of Oxford and NIHR Oxford Biomedical Research Centre (Haematology), Oxford, UK.
  6. Barcelona Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clínic, IDIBAPS, Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Health Care Provider of the European Reference Network on Rare Liver Disorders (ERN-Liver), University of Barcelona, Barcelona, Spain.
  7. Department of Pediatrics, Clinical Chemistry and Blood Coagulation Research, MMK, CLINTEC, Karolinska Institutet, Stockholm, Sweden.
  8. Department of Haematology, Karolinska University Hospital, Stockholm, Sweden.
  9. IRCCS Ca' Granda Maggiore Hospital Foundation, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center and Fondazione Luigi Villa, Milano, Italy.
  10. Department of Haematology, Manchester Royal Infirmary, Manchester, UK.

PMID: 34661370 DOI: 10.1111/jth.15562

Abstract

Prolonged prothrombin time and thrombocytopenia are common in patients with cirrhosis. These parameters do not reflect the overall hemostatic rebalance or bleeding risk in the periprocedural setting; however, attempts to correct these parameters remain frequent. We review the literature on periprocedural bleeding risk, bleeding risk factors, and the risk and benefits of hemostatic interventions in patients with cirrhosis. We provide guidance recommendations on evaluating bleeding risk in this patient group and management of hemostatic abnormalities in the periprocedural setting.

© 2021 International Society on Thrombosis and Haemostasis.

Keywords: cirrhosis; hemorrhage; hemostasis; liver diseases; thrombocytopenia

References

  1. Lisman T, Arefaine B, Adelmeijer J, et al. Global hemostatic status in patients with acute-on-chronic liver failure and septics without underlying liver disease. J Thromb Haemost. 2021;19:85-95. doi:10.1111/jth.15112 - PubMed
  2. Desborough MJR, Hockley B, Sekhar M, et al. Patterns of blood component use in cirrhosis: a nationwide study. Liver International. 2016;36:522-529. - PubMed
  3. Northup PG, Garcia-Pagan JC, Garcia-Tsao G, et al. Vascular liver disorders, portal vein thrombosis, and procedural bleeding in patients with liver disease: 2020 practice guidance by the American Association for the Study of Liver Diseases. Hepatology. 2021;2020:31646. - PubMed
  4. O’Shea RS, Davitkov P, Ko CW, et al. AGA clinical practice guideline on the management of coagulation disorders in patients with cirrhosis. Gastroenterology. 2021;161(5):1615-1627. - PubMed
  5. D'Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol. 2006;44:217-231. - PubMed
  6. Child CG, Turcotte JG. Surgery and portal hypertension. Major Probl Clin Surg. 1964;1:1-85. - PubMed
  7. Kaatz S, Ahmad D, Spyropoulos AC, Schulman S. Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH. J Thromb Haemost. 2015;13:2119-2126. - PubMed
  8. Schulman S, Angerås U, Bergqvist D, et al. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients. J Thromb Haemost. 2010;8:202-204. - PubMed
  9. Massicotte L, Denault AY, Beaulieu D, et al. Transfusion rate for 500 consecutive liver transplantations: experience of one liver transplantation center. Transplantation. 2012;93:1276-1281. - PubMed
  10. Spyropoulos AC, Brohi K, Caprini J, et al. Scientific and Standardization Committee Communication: guidance document on the periprocedural management of patients on chronic oral anticoagulant therapy: recommendations for standardized reporting of procedural/surgical bleed risk and patient-specific thromboembolic risk. J Thromb Haemost. 2019;17:1966-1972. - PubMed
  11. Patel IJ, Rahim S, Davidson JC, et al. Society of interventional radiology consensus guidelines for the periprocedural management of thrombotic and bleeding risk in patients undergoing percutaneous image-guided interventions - part ii: recommendations. J Vasc Interv Radiol. 2019;30:1168-1184. - PubMed
  12. Hibbert RM, Atwell TD, Lekah A, et al. Safety of ultrasound-guided thoracocentesis in patients with abnormal preprocedural coagulation parameters. Chest. 2013;144:456-463. - PubMed
  13. Pillai AK, Andring B, Faulconer N, et al. Utility of intravascular US-guided portal vein access during transjugular intrahepatic portosystemic shunt creation: retrospective comparison with conventional technique in 109 patients. J Vasc Interv Radiol. 2016;27:1154-1159. - PubMed
  14. Capoor MN, Stonemetz JL, Baird JC, et al. Prothrombin time and activated partial thromboplastin time testing: a comparative effectiveness study in a million-patient sample. PLoS One. 2015;10:e0133317. - PubMed
  15. De Pietri L, Bianchini M, Montalti R, et al. Thrombelastography-guided blood product use before invasive procedures in cirrhosis with severe coagulopathy: a randomized, controlled trial. Hepatology. 2016;63:566-573. - PubMed
  16. Vuyyuru SK, Singh AD, Gamanagatti SR, Rout G, Gunjan D, Shalimar. A randomized control trial of thromboelastography-guided transfusion in cirrhosis for high-risk invasive liver-related procedures. Dig Dis Sci. 2019. - PubMed
  17. Zanetto A, Rinder HM, Senzolo M, Simioni P, Garcia-Tsao G. Reduced clot stability by thromboelastography as a potential indicator of procedure-related bleeding in decompensated cirrhosis. Hepatology Communications. 2021;5:272-282. - PubMed
  18. Elbaz C, Sholzberg M. An illustrated review of bleeding assessment tools and common coagulation tests. Res Pract Thromb Haemost. 2020;4:761-773. - PubMed
  19. Roberts LN, Bernal W. Incidence of bleeding and thrombosis in patients with liver disease. Semin Thromb Hemost. 2020;46:656-664. - PubMed
  20. Ewe K. Bleeding after liver biopsy does not correlate with indices of peripheral coagulation. Dig Dis Sci. 1981;26:388-393. - PubMed
  21. Rockey DC, Caldwell SH, Goodman ZH, Nelson RC, Smith AD. AASLD position paper: liver biopsy. Hepatology. 2009;49(3):1017-1044. - PubMed
  22. Vieira da Rocha EC, D'Amico EA, Caldwell SH, et al. A prospective study of conventional and expanded coagulation indices in predicting ulcer bleeding after variceal band ligation. Clin Gastroenterol Hepatol. 2009;7:988-993. - PubMed
  23. Wadhawan M, Dubey S, Sharma BC, Sarin SK, Sarin SK. Hepatic venous pressure gradient in cirrhosis: correlation with the size of varices, bleeding, ascites, and child's status. Dig Dis Sci. 2006;51:2264-2269. - PubMed
  24. Lin S, Wang M, Zhu Y, et al. Hemorrhagic complications following abdominal paracentesis. in acute on chronic liver failure: a propensity score analysis. Medicine (Baltimore). 2015;94:e2225. - PubMed
  25. Giannini EG, Giambruno E, Brunacci M, et al. Low fibrinogen levels are associated with bleeding after varices ligation in thrombocytopenic patients. Ann Hepatol. 2018;17:830-835. - PubMed
  26. Fisher C, Patel VC, Stoy SH, et al. Balanced haemostasis with both hypo- and hyper-coagulable features in critically ill patients with acute-on-chronic-liver failure. J Crit Care. 2018;43:54-60. - PubMed
  27. Drolz A, Horvatits T, Roedl K, et al. Coagulation parameters and major bleeding in critically ill patients with cirrhosis. Hepatology. 2016;64:556-568. - PubMed
  28. Budnick IM, Davis JPE, Sundararaghavan A, et al. Transfusion with cryoprecipitate for very low fibrinogen levels does not affect bleeding or survival in critically Ill cirrhosis patients. Thromb Haemost. 2021;121:1317-1325. - PubMed
  29. Bashour FN, Teran JC, Mullen KD. Prevalence of peripheral blood cytopenias (hypersplenism) in patients with nonalcoholic chronic liver disease. Am J Gastroenterol. 2000;95:2936-2939. - PubMed
  30. Afdhal N, McHutchison J, Brown R, et al. Thrombocytopenia associated with chronic liver disease. J Hepatol. 2008;48:1000-1007. - PubMed
  31. Basili S, Raparelli V, Napoleone L, et al. Platelet count does not predict bleeding in cirrhotic patients: results from the PRO-LIVER study. Am J Gastroenterol. 2018;113:368-375. - PubMed
  32. Slichter SJ, Kaufman RM, Assmann SF, et al. Dose of prophylactic platelet transfusions and prevention of hemorrhage. N Engl J Med. 2010;362:600-613. - PubMed
  33. Lisman T, Bongers TN, Adelmeijer J, et al. Elevated levels of von Willebrand Factor in cirrhosis spport platelet adhesion despite reduced functional capacity. Hepatology. 2006;44:53-61. - PubMed
  34. Tripodi A, Primignani M, Chantarangkul V, et al. Thrombin generation in patients with cirrhosis: the role of platelets. Hepatology. 2006;44:440-445. - PubMed
  35. Tripodi A, Primignani M, Chantarangkul V, et al. Global hemostasis tests in patients with cirrhosis before and after prophylactic platelet transfusion. Liver Int. 2013;33:362-367. - PubMed
  36. Zanetto A, Rinder HM, Campello E, et al. Acute kidney injury in decompensated cirrhosis is associated with both hypo- and hyper-coagulable features. Hepatology. 2020;72:1327-1340. - PubMed
  37. Hung A, Garcia-Tsao G. Acute kidney injury, but not sepsis, is associated with higher procedure-related bleeding in patients with decompensated cirrhosis. Liver Int. 2018;38:1437-1441. - PubMed
  38. Montalto P, Vlachogiannakos J, Cox DJ, Pastacaldi S, Patch D, Burroughs AK. Bacterial infection in cirrhosis impairs coagulation by a heparin effect: a prospective study. J Hepatol. 2002;37:463-470. - PubMed
  39. Bianchini M, Cavani G, Bonaccorso A, et al. Low molecular weight heparin does not increase bleeding and mortality post-endoscopic variceal band ligation in cirrhotic patients. Liver Int. 2018;38:1253-1262. - PubMed
  40. Green L, Bolton-Maggs P, Beattie C, et al. British Society of Haematology Guidelines on the spectrum of fresh frozen plasma and cryoprecipitate products: their handling and use in various patient groups in the absence of major bleeding. Br J Haematol. 2018;181:54-67. - PubMed
  41. von Meijenfeldt FA, van den Boom BP, Adelmeijer J, Roberts LN, Lisman T, Bernal W. Prophylactic fresh frozen plasma and platelet transfusion have a prothrombotic effect in patients with liver disease. J Thromb Haemost. 2020;19:664-676. - PubMed
  42. Rassi AB, d'Amico EA, Tripodi A, et al. Fresh frozen plasma transfusion in patients with cirrhosis and coagulopathy: effect on conventional coagulation tests and thrombomodulin-modified thrombin generation. J Hepatol. 2019;72:85-94. - PubMed
  43. Zimmon DS, Kessler RE. The portal pressure-blood volume relationship in cirrhosis. Gut. 1974;15:99-101. - PubMed
  44. Mohanty A, Kapuria D, Canakis A, et al. Fresh frozen plasma transfusion in acute variceal haemorrhage: Results from a multicentre cohort study. Liver Int. 2021;41(8):1901-1908. - PubMed
  45. Nguyen-Buckley C, Gao W, Agopian V, Wray C, Steadman RH, Xia VW. Major thromboembolic complications in liver transplantation: the role of rotational thromboelastometry and cryoprecipitate transfusion. Transplantation. 2020;105(8):1771-1777. - PubMed
  46. Simonetto DA, Singal AK, Garcia-Tsao G, Caldwell SH, Ahn J, Kamath PS. ACG clinical guideline: disorders of the hepatic and mesenteric circulation. Am J Gastroenterol. 2020;115:18-40. - PubMed
  47. Hugenholtz GCG, Macrae F, Adelmeijer J, et al. Procoagulant changes in fibrin clot structure in patients with cirrhosis are associated with oxidative modifications of fibrinogen. J Thromb Haemost. 2016;14:1054-1066. - PubMed
  48. Desborough MJ, Kahan BC, Stanworth SJ, Jairath V. Fibrinogen as an independent predictor of mortality in decompensated cirrhosis and bleeding. Hepatology. 2017;65:1079-1080. - PubMed
  49. Fabes J, Brunskill SJ, Curry N, Doree C, Stanworth SJ. Pro-coagulant haemostatic factors for the prevention and treatment of bleeding in people without haemophilia. Cochrane Database Syst Rev. 2018;12:CD010649. - PubMed
  50. Hartmann M, Walde C, Dirkmann D, Saner FH. Safety of coagulation factor concentrates guided by ROTEM-analyses in liver transplantation: results from 372 procedures. BMC Anesthesiol. 2019;19:97. - PubMed
  51. Bosch J, Thabut D, Albillos A, et al. Recombinant factor VIIa for variceal bleeding in patients with advanced cirrhosis: a randomized, controlled trial. Hepatology. 2008;47:1604-1614. - PubMed
  52. Bosch J, Thabut D, Bendtsen F, et al. Recombinant factor VIIa for upper gastrointestinal bleeding in patients with cirrhosis: a randomized, double-blind trial. Gastroenterology. 2004;127:1123-1130. - PubMed
  53. Planinsic RM, van der Meer J, Testa G, et al. Safety and efficacy of a single bolus administration of recombinant factor VIIa in liver transplantation due to chronic liver disease. [see comment]. Liver Transpl. 2005;11:895-900. - PubMed
  54. Lodge JPA, Jonas S, Jones RM, et al. Efficacy and safety of repeated perioperative doses of recombinant factor VIIa in liver transplantation. Liver Transpl. 2005;11:973-979. doi:10.1002/lt.20470 - PubMed
  55. WOMAN trial collaborators. Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial. The Lancet. 2017;389:2105-2116. - PubMed
  56. CRASH-2 trial collaborators. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet. 2010;376:23-32. - PubMed
  57. HALT-IT trial collaborators. Effects of a high-dose 24-h infusion of tranexamic acid on death and thromboembolic events in patients with acute gastrointestinal bleeding (HALT-IT): an international randomised, double-blind, placebo-controlled trial. Lancet. 2020;395:1927-1936. - PubMed
  58. O'Leary JG, Greenberg CS, Patton HM, Caldwell SH. AGA clinical practice update: coagulation in cirrhosis. Gastroenterology. 2019;157:34-43.e1. doi:10.1053/j.gastro.2019.03.070 - PubMed
  59. Baharoglu MI, Cordonnier C, Salman R-S, et al. Platelet transfusion versus standard care after acute stroke due to spontaneous cerebral haemorrhage associated with antiplatelet therapy (PATCH): a randomised, open-label, phase 3 trial. Lancet. 2016;387:2605-2613. - PubMed
  60. Napolitano G, Iacobellis A, Merla A, et al. Bleeding after invasive procedures is rare and unpredicted by platelet counts in cirrhotic patients with thrombocytopenia. Eur J Intern Med. 2017;38:79-82. - PubMed
  61. Cocero N, Bezzi M, Martini S, Carossa S. Oral surgical treatment of patients with chronic liver disease: assessments of bleeding and its relationship with thrombocytopenia and blood coagulation parameters. J Oral Maxillofac Surg. 2017;75:28-34. - PubMed
  62. Massoud OI, Zein NN. The effect of transjugular intrahepatic portosystemic shunt on platelet counts in patients with liver cirrhosis. Gastroenterol Hepatol. 2017;13:286-291. - PubMed
  63. Khemichian S, Terrault NA. Thrombopoietin receptor agonists in patients with chronic liver disease. Semin Thromb Hemost. 2020;46:682-692. - PubMed
  64. Nilles KM, Flamm SL. Thrombocytopenia in chronic liver disease: new management strategies. Clin Liver Dis. 2020;24:437-451. - PubMed
  65. Miller JB, Figueroa EJ, Haug RM, Shah NL. Thrombocytopenia in chronic liver disease and the role of thrombopoietin agonists. Gastroenterol Hepatol. 2019;15:326-332. - PubMed
  66. Loffredo L, Violi F. Thrombopoietin receptor agonists and risk of portal vein thrombosis in patients with liver disease and thrombocytopenia: a meta-analysis. Dig Liver Dis. 2019;51:24-27. - PubMed
  67. Lindquist I, Olson SR, Li A, et al. The efficacy and safety of thrombopoeitin receptor agonists in patients with chronic liver disease undergoing elective procedures: a systematic review and meta-analysis. Platelets. 2021. doi:10.1080/09537104.2020.1859102 - PubMed
  68. Rose PD, Au M, Woodman RJ, Tee D, Chinnaratha MA. Pre-procedural use of thrombopoietin-receptor agonists in cirrhosis and severe thrombocytopenia: a systematic review and meta-analysis. Dig Liver Dis. 2021. in press. - PubMed

Publication Types